alpha-Glucosidase inhibitors (Q41603314)

4 October 2017

1 reference

title

alpha-Glucosidase inhibitors (English)

1 reference

4 October 2017

Lebovitz HE

1

1 reference

4 October 2017

1 September 1997

1 reference

Endocrinology and Metabolism Clinics of North America

4 October 2017

1 reference

4 October 2017

26

1 reference

4 October 2017

539-551

1 reference

4 October 2017

3

1 reference

A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.

4 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

Post-meal coagulation activation in diabetes mellitus: the effect of acarbose

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

The enteroinsular axis revisited. A novel role for an incretin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

The effect of ten days of fasting on various aspects of carbohydrate metabolism in obese diabetic subjects with significant fasting hyperglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

The incretin notion and its relevance to diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

An importance of carbohydrate ingestion for the expression of the effect of alpha-glucosidase inhibitor in NIDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

Undiagnosed NIDDM: clinical and public health issues.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

Effects of acarbose on starch hydrolysis. Study in healthy subjects, ileostomy patients, and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

Acarbose in the treatment of type I diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

Effects of acarbose on fecal nutrients, colonic pH, and short-chain fatty acids and rectal proliferative indices

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

The Whitehall Study: Ten Year Follow-up Report on Men With Impaired Glucose Tolerance With Reference to Worsening to Diabetes and Predictors of Death

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

A new approach to the treatment of nocturnal hypoglycemia using alpha-glucosidase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

Effects of alpha-glucosidase inhibition and viscous fibre on diabetic control and postprandial gut hormone responses

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

The effect of the timing and the administration of acarbose on postprandial hyperglycaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

Alpha-glucosidase inhibition as an adjunct to the treatment of type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

One-year acarbose treatment raises fasting serum acetate in diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970266-8

7 January 2021

10.1016/S0889-8529(05)70266-8

Identifiers

DOI

1 reference

4 October 2017

1 reference

PubMed ID

9314014